Abstract
The search for an ideal radioisotope for systemic radiotherapy continues. As a generator-produced radioisotope emitting both beta and gamma rays and having a short physical half-life of 16.9 h, rhenium-188 is a very good potential candidate for systemic radiotherapy. In this study, we labeled hydroxyethylidene diphosphonate (HEDP) with188Re and analyzed the biodistribution and bone uptake following intravenous injection in rats to assess its potential for clinical use. The rats were injected with approximately 14.8 MBq (0.4 mCi)188Re-HEDP in a volume of 0.1 ml intravenously and then sacrificed at 1 h, 24 h, or 48 h (four rats at each time). Samples (about 0.1 g) of lung, liver, kidney, spleen, testis, muscle, stool, and bone (thoracic vertebra) were taken and weighed carefully. In addition, a 1-ml sample of blood was drawn from the heart and 1 ml of urine was taken from the urinary bladder immediately after killing. Tissue concentrations were calculated and expressed as percent injected dose per gram or per milliliter (% ID/g or ml). Bone lesions were created in the right tibial bone in three rabbits to calculate the lesion to normal uptake ratio (UN ratio). The biodistribution data showed that the radioactivity in the bone tissue was as high as 1.877% ID/g at 1 h and that it climbed to 2.017% ID/g at 4 h. The activity level in the kidney was highest at 1 h but declined rapidly throughout the study. The radioactivities in the lung, liver, muscle, spleen, testis, blood, and stool were all lower than 0.3% ID/g at I h and also declined rapidly. The biological half-life in bone was the longest (60.86 h). In contrast, the biological half-lives in muscle and blood were short (2.99 h and 6.21 h respectively). The concentrations of radioactivity in muscle, spleen, testis, and stool were quite low throughout the study. Most of the radiotracer was excreted by the urinary system. The L/N ratio was 4.23±0.21 in rabbits injected with188Re-HEDP and 4.25±0.23 in those injected with technetium-99m methylene diphosphonate. In conclusion, we would suggest that188Re-HEDP is a very good potential candidate for the treatment of bone metastases because of the following characteristics: (1) it is generator produced; (2) it has a short half-life; (3) it emits gamma rays suitable for imaging; (4) there is highly selective uptake in the skeletal system and bone lesions; and (5) it has a low non-target uptake and rapid clearance in nonosseous tissue.
Similar content being viewed by others
References
Hendrikson FR, Sheinkop MB. Management of osseous metastasis.Semin Oncol 1975; 2: 399–404.
Pollen JJ, Schmidt JD. Bone pain in metastatic cancer of prostate. Urology 1979; 13: 129–134.
Hendrickson FR, Shehata WM, Kirchner AB. Radiation therapy for osseous metastasis.Int J Radiat Oncol Biol Phys 1976; 1: 275–278.
Gilbert HA, Kagan AR, Nussbaum H, Rao AR, Satzman J, Chan P, Allen B, Forsythe A. Evaluation of radiation therapy for bone metastases: pain relief and quality of life.Am J Roentgenol 1977; 129: 1095–1096.
Morin LJ, Stevens JC. Radioactive phosphorus in the treatment of metastasis to bone from carcinoma of the prostate.J Urol 1967; 97: 130–132.
Joshi DP, Seery WH, Goldberg LG. Evaluation of 32-phosphorus for intractable pain secondary to prostatic carcinoma metastasis.JAMA 1965; 193: 621–623.
Lewington VJ, McEwan AJ, Ackery DM, Bayly RJ, Keeling DH, Macleod PM, Porter AT, Zivanovic MA. A prospective, randomized double-blind crossover study to examine the efficacy of strontium in palliation in patients with advanced prostate cancer metastatic to bone.Eur J Cancer 1991; 27: 954–958.
Laing AH, Ackery DM, Bayly RJ, Buchanan RB, Lewington VJ, McEwan AJ, Macleod PM, Zivanovic MA. Strontium-89 chloride for pain palliation in prostatic skeletal malignancy.Br J Radiol 1991; 64: 816–822.
Robinson RG, Spicer JA, Preston DF, Wegst AV, Martin NL. Treatment of metastatic bone pain with strontium-89.Nucl Med Biol 1987; 14: 219–222.
Turner JH, Claringbold PG, Hetherington EL, Sorby P, Martindale AA. A phase I study of samarium-153 ethylenediaminetetramethylene phosphonate therapy for disseminated skeletal metastases.J Clin Oncol 1989; 7: 1926–1931.
Maxon HR, Deutsch EA, Thomas SR, et al. Rhenium-186(Sn)HEDP for treatment of multiple metastatic foci in bone: human biodistribution and dosimerric studies.Radiology 1988; 501–507.
Maxon HR, Schroder LE, Thomas SR, et al. Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: initial experience in 20 patients with hormone-resistant prostate cancer.Radiology 1990; 176: 155–159.
Maxon HR, Schroder LE, Hertzberg VS, Hertzberg VS, Deutsch EA, Scher HI, Samaratunga RC, Libson KF, Williams CC, Moulton JS. Rhenium-186(Sn)HEDP for treatment of painful osseous metastases; results of a double-blind crossover comparison with placebo.J Nucl Med 1991; 32: 1877–1881.
Ketring AR. Samarium-153-EDTMP and Re-186-HEDP as bone therapeutic radiopharmaceuticals.Nucl Med Biol 1987; 14: 223–232.
Callahan AP, Rice D, Knapp FF jr. Rhenium-188 for therapeutic applications from an alumina based tungsten-188/Re-188 radionuclide generator. NucCompact-Eur/Am.Commun Nucl Med 1989; 20: 3–6.
Subramanian G, McAfee JG, Thomas FD, Feld TA, Zapf LC, Palladino E. New diphosphonate compounds for skeletal imaging, comparison with methylene diphosphonate.Radiology 1983; 149: 823–829.
Kirschner A, Ice R, Beierwaltes W. Radiation dosimetry of 1311-19-iodocbolesterol: the pitfalls of using tissue concentration data, the author's reply.J Nucl Med 1975; 16: 248–249.
Loevinger R, Budinger T, Watson E.MIRD primer for adsorbed dose calculation. Society of Nuclear Medicine, 1988.
Cloutier R, Smith S, Watson E, Snyder W, Warger G. Dose of the fetus from radionuclides in the bladder.Health Phys 1973; 25: 147–161.
Stabin MG. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine.J Nucl Med 1996; 37: 538–546.
Troutner DA. Chemical and physical properties of radionuclides.Nucl Med Biol 1987; 14: 171–176.
Fritzberg AR, Berninger RW, Hadley SW, Wester DW. Approaches to radiolabeling of antibodies for diagnosis and therapy of cancer.Pharm Res 1988; 5: 325–334.
Mathieu L, Chevalier P, Galy G, Berger M. Preparation of rhenium-186 labelled EHDP and its possible use in the treatment of osseous neoplasms. Int J Appl Rad Iso 1979; 30: 725–727.
Englaro EE, Schroder LE, Thomas SR, Williams CC, Maxon HR. Safety and efficacy of repeated sequential administrations of Re-186(Sn)HEDP as palliative therapy for painful skeletal metastases. Initial case reports of two patients.Clin Nucl Med 1992; 17: 41–44.
Maxon HF, Thomas SR, Hertzberg VS, Schroder LE, Englaro EE, Samaratunga R, Scher HI, Moulton JS, Deutsch EA, Deutsch KF. Rhenium-186 hydroxyethelidine diphosphonate for the treatment of painful osseous metastases.Semin Nucl Med 1992; 23: 33–40.
de Klerk JMH, van Dijk A, van het Schip AD, Zonnenberg BA, van Rijk PP. Pharmacokinetic of rhenium- 186-HEDP after administration of rhenium-186 HEDP to patients with bone metastases.J Nucl Med 1992; 33: 646–651.
Lewington VJ. Targeted radionuclide therapy for bone metastases.Eur J Nucl Med 1993; 20: 66–74.
de Klerk JMH, Zonnenberg BA, van het Schip AD, van Dijk A, Han SH, Quirijnen JM, Blijham GH, van Rijk PP. Dose escalation study of rhenium-186-hydroxyethylidene diphosphonate in patients with metastic prostate cancer.Eur J Nucl Med 1994; 21: 1121–1125.
Madrazo A, Schwarz G, Churg J. Radiation nephritis: a review.J Urol 1975; 114: 822–827.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lin, WY., Lin, CP., Yeh, SJ. et al. Rhenium-188 hydroxyethylidene diphosphonate: a new generator-produced radiotherapeutic drug of potential value for the treatment of bone metastases. Eur J Nucl Med 24, 590–595 (1997). https://doi.org/10.1007/BF00841394
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00841394